Dabur India Limited (DABUR)

Fast Moving Consumer Goods · Personal Products · NSE · Updated 4 August 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹409.65 ↓ 22.66% (1Y)

🎯 Key Takeaways

Dabur India is transitioning from a mature FMCG player into a growth-oriented phase driven by rural market resilience, premiumization, and international expansion, as evidenced by double-digit international revenue growth and sustained margin improvement. Despite a challenging macro environment, the company is executing a strategic shift toward higher-margin segments and volume-led recovery, particularly in hair care, oral care, and health supplements.
Revenue grew 10.8% QoQ to ₹3,355 in Q3FY25.
⚠️ Execution risk around leadership transition in the India business, as the new CEO takes charge post-restructuring, could impact strategic continuity.

Market Cap

₹82,955

P/E Ratio

46.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About DABUR 📊 Interactive Charts

📖 The Story

Dabur India is transitioning from a mature FMCG player into a growth-oriented phase driven by rural market resilience, premiumization, and international expansion, as evidenced by double-digit international revenue growth and sustained margin improvement. Despite a challenging macro environment, the company is executing a strategic shift toward higher-margin segments and volume-led recovery, particularly in hair care, oral care, and health supplements.

📰 What's Happening

In Q1 FY27, Dabur reported consolidated revenue growth of 10.6% YoY, with international sales growing 15.5% and operating margin expanding by 110 bps. Management highlighted rural demand outperforming urban markets and premiumization initiatives gaining traction across key categories. The company also appointed Herjit S. Bhalla as CEO-India Business following a board-approved internal restructuring effective July 29, 2026, signaling a potential shift in execution focus for the domestic business. Additionally, Crisil upgraded Dabur’s ESG rating from 'Adequate' to 'Strong', reflecting improved sustainability performance.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	2,678	3,130	3,204	3,255	2,815	3,349	3,029	3,355
Operating Profit	531	715	777	795	596	784	704	810
OPM %	15.3%	19.3%	20.6%	20.5%	16.6%	19.6%	18.2%	20.3%
Net Profit	293	457	507	506	341	494	418	516
EPS	₹1.70	₹2.62	₹2.91	₹2.90	₹1.97	₹2.82	₹2.40	₹2.95

Dabur’s financial trajectory shows a clear inflection point: revenue and operating profit have accelerated sequentially, with Q1 FY27 marking the highest YoY growth in recent quarters (10.6% revenue growth), accompanied by 15% PAT growth and 110 bps OPM expansion to 20.3%. This contrasts with the flatter performance in FY24, where growth was constrained by inflation. The improvement aligns with management’s narrative of resilient consumption and volume-driven recovery, particularly in rural and premium segments, enabling margin recovery despite macro pressures.

🔮 Management Outlook & What's Next

Management expects sequential acceleration in revenue growth to continue, targeting double-digit growth for the full fiscal year FY27. This confidence is underpinned by strong rural demand, successful premiumization strategies, and expanding international footprint. No formal long-term guidance beyond this was provided in the latest filing, but the tone reflects optimism around sustaining volume-led momentum in both domestic and global markets.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Personal Products

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Godrej Consumer Products Limited	1.06 L Cr	-234.6	—	—	—
Dabur India Limited	82,955	46.1	—	—	—
Colgate Palmolive (India) Limited	58,749	44.3	—	—	—
Procter & Gamble Hygiene and Health Care Limited	31,506	36.7	—	—	—
Gillette India Limited	25,438	41.0	—	—	—
Emami Limited	18,684	23.6	—	—	—
Cupid Limited	16,184	668.7	—	—	—
Honasa Consumer Limited	11,518	145.1	—	—	—
Bajaj Consumer Care Limited	7,020	58.5	—	—	—
JHS Svendgaard Laboratories Limited	80	-5.8	—	—	—

🔗 Peer Stock Analyses

GODREJCP COLPAL PGHH GILLETTE EMAMILTD

⚠️ Risk Factors

1. Execution risk around leadership transition in the India business, as the new CEO takes charge post-restructuring, could impact strategic continuity. 2. Margin sustainability amid persistent inflationary pressures, despite current resilience in consumption trends. 3. Slower-than-expected recovery in urban demand, which remains a key growth lever. 4. Competitive intensity in core categories like hair and oral care, which may pressure pricing and market share.

📋 Recent Filings

🧠 Analyst's Read

Dabur is demonstrating early signs of a strategic turnaround, with volume-driven growth in rural and premium segments offsetting macro headwinds. The key watchpoint will be whether the new leadership can sustain this momentum and deliver consistent double-digit growth without margin erosion. Investors should monitor urban demand trends and international expansion progress in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on DABUR

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-04.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DABUR files new disclosures

Track DABUR filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DABUR — Free

Free account · 2 AI queries/day